



UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #

19/224,580

RECEIPT DATE / TIME

07/22/2026 07:16:18 AM Z ET

ATTORNEY DOCKET #

SLNO-034/12US 333072-2199

Title of Invention

METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME

Application Information

APPLICATION TYPE Utility - Nonprovisional Application
under 35 USC 111(a)

PATENT # 12419895

CONFIRMATION # 1503

FILED BY SUZANNE ONEILL

PATENT CENTER # 79130050

FILING DATE 05/30/2025

CUSTOMER # 58249

FIRST NAMED
INVENTOR Neil M. COWEN

CORRESPONDENCE
ADDRESS -

AUTHORIZED BY Christine Goddard

Documents

TOTAL DOCUMENTS: 1

DOCUMENT	PAGES	DESCRIPTION	SIZE (KB)
46696-0264009_Disclaimer.pdf	2	Statutory disclaimers per Manual of Patent Examining Procedure(MPEP) 1490.	277 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
46696-0264009_Disclaimer.pdf	31AEC046F0B2E81704FECCCC07D4264C60AF49CCBE9699CA3 019170BCCDADED3783EA70B06DD38E09104E94C391EE7618 E843EE76DE105785FAE6BF5B733C7950

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized
Solenio Therapeutics, Inc.
Exhibit 2093
Apotex v. Soleno
PGR2026-00034
Ex. 2093-001

by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.



UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC PAYMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
19/224,580	07/22/2026 07:16:18 AM Z ET	SLNO-034/12US 333072-2199

Title of Invention

METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	12419895
CONFIRMATION #	1503	FILED BY	SUZANNE ONEILL
PATENT CENTER #	79130050	AUTHORIZED BY	Christine Goddard
CUSTOMER #	58249	FILING DATE	05/30/2025
CORRESPONDENCE ADDRESS	-	FIRST NAMED INVENTOR	Neil M. COWEN

Payment Information

PAYMENT METHOD	PAYMENT TRANSACTION ID	PAYMENT AUTHORIZED BY
DA / 061050	E20267L817186502	SUZANNE ONEILL

FEE CODE	DESCRIPTION	ITEM PRICE(\$)	QUANTITY	ITEM TOTAL(\$)
1814	STATUTORY DISCLAIMER, INCLUDING TERMINAL DISCLAIMER	183.00	1	183.00
TOTAL AMOUNT:				\$183.00

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C.

371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

DISCLAIMER IN A PATENT UNDER 37 CFR 1.321(a)	
Name of Patentee <div style="text-align: right;">Solenio Therapeutics, Inc.</div>	Docket Number (optional) <div style="text-align: right;">46696-0264009</div>
Patent Number <div style="text-align: right;">12,419,895</div>	Date Patent Issued <div style="text-align: right;">September 23, 2025</div>
Title of Invention <div style="text-align: right;">Methods for Treating Subjects with Prader-Willi Syndrome</div>	
<p>Patentee hereby disclaims:</p> <p>☒ the following complete claim(s) in the above-identified patent: <u>1, 4-15, and 26</u>.</p> <p>☐ the terminal part of the term of the above-identified patent beginning on the date: _____.</p> <p>☐ the entire term of the above-identified patent.</p> <p>The disclaimer is binding on the patentee and its successors or assigns. Assignee of Record</p> <p>The extent of patentee's ownership interest in the above-identified patent is: <u>Reel/Frame 073832/0312</u>.</p> <p>The fee for this disclaimer is set forth in 37 CFR 1.20(d) and is being paid in the following manner:</p> <p>☐ payment by the USPTO patent electronic filing system.</p> <p>☒ the Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account No. <u>06-1050</u>.</p> <p>☐ payment by credit card. Form PTO-2038 is attached.</p> <p>☐ a check in the amount of the fee is enclosed.</p> <p>WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on form PTO-2038.</p> <p>The undersigned is:</p> <p>☐ patentee. If patentee is a juristic entity, the undersigned is authorized to act on behalf of the juristic entity.</p> <p>☒ attorney or agent of record.</p>	
Signature <div style="text-align: right;">/Christine A. Goddard/</div>	Date <div style="text-align: right;">July 22, 2026</div>
Name (printed/typed) <div style="text-align: right;">Christine A. Goddard</div>	Practitioner registration number <div style="text-align: right;">46,731</div>
Note: See 37 CFR 1.4(d) for signature requirements and certifications.	

A Federal agency may not conduct or sponsor, and a person is not required to respond to, nor shall a person be subject to a penalty for failure to comply with an information collection subject to the requirements of the Paperwork Reduction Act of 1995, unless the information collection has a currently valid OMB Control Number. The OMB Control Number for this information collection is 0651-0031. Public burden for this form is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the information collection. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden to the Chief Administrative Officer, United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450 or email InformationCollection@uspto.gov. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. If filing the completed form by mail, send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. The United States Patent and Trademark Office (USPTO) collects the information in this record under authority of 35 U.S.C. 2. The USPTO's system of records is used to manage all applicant and owner information including name, citizenship, residence, post office address, and other information with respect to inventors and their legal representatives pertaining to the applicant's/owner's activities in connection with the invention for which a patent is sought or has been granted. The applicable Privacy Act System of Records Notice for the information collected in this form is COMMERCE/PAT-TM-7 Patent Application Files, available in the Federal Register at 78 FR 19243 (March 29, 2013), <https://www.govinfo.gov/content/pkg/FR-2013-03-29/pdf/2013-07341.pdf>.

Routine uses of the information in this record may include disclosure to: 1) law enforcement, in the event that the system of records indicates a violation or potential violation of law; 2) a federal, state, local, or international agency, in response to its request; 3) a contractor of the USPTO having need for the information in order to perform a contract; 4) the Department of Justice for determination of whether the Freedom of Information Act (FOIA) requires disclosure of the record; 5) a Member of Congress submitting a request involving an individual to whom the record pertains, when the individual has requested the Member's assistance with respect to the subject matter of the record; 6) a court, magistrate, or administrative tribunal, in the course of presenting evidence, including disclosures to opposing counsel in the course of settlement negotiations; 7) the Administrator, General Services Administration (GSA), or their designee, during an inspection of records conducted by GSA under authority of 44 U.S.C. 2904 and 2906, in accordance with the GSA regulations and any other relevant (i.e., GSA or Commerce) directive, where such disclosure shall not be used to make determinations about individuals; 8) another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)); 9) the Office of Personnel Management (OPM) for personnel research purposes; and 10) the Office of Management and Budget (OMB) for legislative coordination and clearance.

If you do not furnish the information requested on this form, the USPTO may not be able to process and/or examine your submission, which may result in termination of proceedings, abandonment of the application, and/or expiration of the patent.